（编辑 任世碧） 证券日报网讯 9月3日晚间，多瑞医药发布公告称，截至本公告日，公司对外担保额度为56，500万元， 实际发生的对外担保余额23，230万元，占公司最近一期经审计净资产的比例为34.33%；公司对合并报 表外单位实际发生的担保余额为0.00万元；公司无逾期担保贷款，无涉及诉讼的担保金额及因担保而被 判决败诉而应承担的损失金额。 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-070 西藏多瑞医药股份有限公司 关于向控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 西藏多瑞医药股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日召开第二届董事会第十八次会议和第二届监事会第十七次会议，审 议通过了《关于向控股子公司提供担保的议案》，同意公司为控股子 公司湖北鑫承达化工有限公司（以下简称"鑫承达"）向银行申请综合 授信提供合计不超过 1,500 万元人民币的连带责任保证担保，鑫承达 少数股东武汉市盛祥化工有限公司、武汉金盛兴自控工程有限公司按 出资比例提供同等担保或者反担保。具体内容详见公司同日在巨潮资 讯网（www.cninfo.com.cn）披露的相关公告。 二、对外担保进展情况 近日，公司与中国工商银行股份有限公司宜城支行（以下简称"工 商银行宜城支行"）签署了《最高额保证合同》，公司为控股子公司鑫 承达向工商银行宜城支行申请人民币 530 万元的综合授信额度提供 连带责任保证担保，保证期间以公司与工商银行宜城 ...

Group 1 - Kangchen Pharmaceutical and Puris reached the daily limit increase, while Duri Pharmaceutical rose over 10% [1] - Huahai Pharmaceutical, Haoyuan Pharmaceutical, Jimin Health, Warner Pharmaceuticals, and Medisyn also experienced gains [1]

（文章来源：每日经济新闻） 每经AI快讯，8月29日，A股化学制药板块触底反弹，向日葵涨20%涨停，多瑞医药涨超13%，华海药 业、同和药业均涨9%，华纳药厂、立方制药等涨。 ...

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in its core product market and the need for strategic adjustments to improve financial performance [1][3]. Financial Performance - The company recorded a revenue of 107 million yuan, a year-on-year decrease of 29.13% [1]. - The net profit attributable to the parent company was -42.5 million yuan [1]. Product and Market Analysis - The primary revenue source for the company is the sodium acetate injection, which has maintained a leading market share [3]. - The product has been included in the 10th batch of the national drug centralized procurement list, which has set a foundation for future sales but has led to profit compression due to a "price-for-volume" strategy [3]. Strategic Initiatives - To mitigate the impact of reliance on a single product, the company is accelerating its business layout in raw materials and new formulations through acquisitions [3]. - The acquisitions of Xinchengda and Sichuan Duori have initiated an integrated development model for raw materials and formulations [3]. - New products such as amisulpride injection, sodium bicarbonate injection, and levetiracetam oral solution are in the review stage, which will enhance the product pipeline upon approval [3]. High-End Market Positioning - The company is entering the high-end peptide raw material market, aligning with policy directions and aiming for performance growth [3]. - Peptide drugs, which are complex to synthesize and have historically been dominated by Western companies, present a new opportunity for domestic firms [3]. Future Outlook - The company anticipates that the release of national and local policy benefits, along with the maturation of new business areas, will gradually improve its operational status and achieve high-quality development [4].

Group 1 - The core viewpoint of the article highlights the announcement by Duori Pharmaceutical regarding its board meeting and the composition of its revenue for the year 2024 [1] - Duori Pharmaceutical's revenue composition for 2024 indicates that the pharmaceutical manufacturing sector accounts for 57.85% while other sectors contribute 42.15% [1] - As of the report, Duori Pharmaceutical has a market capitalization of 3.3 billion yuan [1] Group 2 - The article also mentions the booming pet industry, valued at 300 billion yuan, and the positive market response from listed companies in this sector [1]

格隆汇8月26日丨多瑞医药(301075.SZ)公布2025年半年度报告，上半年公司实现营业收入1.07亿元，同 比下降29.13%；归属于上市公司股东的净利润-4250.36万元；归属于上市公司股东的扣除非经常性损益 的净利润-4551.73万元；基本每股收益-0.54元。 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-066 西藏多瑞医药股份有限公司 2025 年半年度报告及摘要披露的提示性公告 | | | 西藏多瑞医药股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第二届董事会第二十二次会议、第二届监事会第二十一次 会议，审议通过了《2025 年半年度报告及其摘要》。为使投资者全面 了解公司的经营情况、财务状况等，公司 2025 年半年度报告及其摘 要于 2025 年 8 月 27 日在中国证监会指定的创业板信息披露网站巨潮 资讯网（www.cninfo.com.cn）披露。 敬请投资者注意查阅。 特此公告。 西藏多瑞医药股份有限公司 董事会 2025 年 8 月 27 日 ...

编制单位：西藏多瑞医药股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关 | 上市公司核算的会计 | 2025年期初 | 2025年半年度占 用累计发生金额 | 2025年半年度占 用资金的利息 | 2025年半年度偿 | 2025年半年度期末 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 联关系 | 科目 | 占用资金余额 | （不含利息） | （如有） | 还累计发生金额 | 占用资金余额 | | | | 控股股东、实际控制人及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 前控股股东、实际控制人及其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 其他关联方及其附属企业 | | | | | | ...